Prelude Therapeutics (PRLD) Return on Capital Employed (2020 - 2026)

Prelude Therapeutics has disclosed Return on Capital Employed across 7 years of filings, most recently posting 94.79% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 94.79%, up 620.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 94.79% (up 620.0% YoY), and the FY2025 annual result was 99.19%, down 2966.0% from the prior year.
• Return on Capital Employed came in at 94.79% for Q1 2026 at Prelude Therapeutics, up from 160.77% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 44.09% in Q1 2022 to a low of 160.77% in Q4 2025.
• The 5-year median for Return on Capital Employed is 64.49% (2023), against an average of 78.74%.
• Across the five-year window, Return on Capital Employed soared 831 bps in 2024 and plunged 7384 bps in 2025, its largest moves.
• Prelude Therapeutics' Return on Capital Employed stood at 58.91% in 2022, then increased by 9 bps to 53.71% in 2023, then sank by 62 bps to 86.93% in 2024, then tumbled by 85 bps to 160.77% in 2025, then soared by 41 bps to 94.79% in 2026.
• The last three Return on Capital Employed figures came in at 94.79% (Q1 2026), 160.77% (Q4 2025), and 139.7% (Q3 2025), per Business Quant data.